Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Open accessThe DOI matches its Crossref record; 273 of the 276 references it cites were found in a registry or an index.
Abstract
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, ∼25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-β plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical‐pathological studies of ageing from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD) 6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-β neuritic amyloid plaques (to factor in ADNC), TDP-43 proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy→dementia) and the other indirect pathway that includes hippocampal sclerosis pathology (TDP-43 proteinopathy→hippocampal sclerosis→dementia): in the statistical model, the TDP-43 proteinopathy is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/9bc83b3adf7f42d5a250b59d9652e7a1/limbic-predominant-age-related-tdp-43-encephalopathy-late-consensus-working-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus group, for example, has described hippocampal sclerosis associated with TDP-43 proteinopathy, as limbic-predominant age-related TDP-43 encephalopathy (LATE) dementia, usually found in people older than 80 years, progressing more slowly than Alzheimer's disease, detectable at post-mortem, often mimicking or comorbid with Alzheimer's disease.3”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“50–60% of Alzheimer’s-type dementia (dementia defined clinically as Alzheimer’s disease) is estimated to be attributable to these copathologies.40,42–45”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE is a recently described entity which affects older people and presents with an amnestic picture resembling Alzheimer's disease 178 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Limbic-predominant age-related TDP43 encephalopathy (LATE), defined approximately 3 years ago, is a condition in which typical TDP43 protein inclusions are present with or without coexisting hippocampal sclerosis.29”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The predominant neuropathological change in LATE is TDP-43 proteinopathy, which is associated with a clinical presentation of amnestic dementia that can mimic Alzheimer's dementia.”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“LATE-NC is mostly seen in the oldest-old, whereas in early clinical-pathological correlation studies of dementia (Roth et al., 1966; Blessed et al., 1968), the research subjects had died in their early 70s.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This stratification will enable enrichment for subjects on the ADNC continuum (Sevigny et al., 2016) while excluding subjects likely to have high risk for LATE-NC (Botha et al., 2018).”
BackgroundMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“seen at autopsy with every year of advanced old age (Braak et al., 2011; Nelson et al., 2011a, 2013; Brenowitz et al., 2014; Neltner et al., 2016).”
BackgroundPorta, M. (2026) · doi:10.1093/acref/9780197663639.001.0001 · Cited by 2,175
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citation
Research works printed but not linked: 3
- Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128– 9.
- Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.
- Thom M, Sisodiya S Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield’s Neuropathology. New York: CRC Press; 2015 p. 683– 739.
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedRevised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607
Self-citationTDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A
Ma, X. R., Prudencio, M., Koike, Y., Vatsavayai, S. C., Kim, G., Harbinski, F., Briner, A., Rodriguez, C. M., Guo, C., Akiyama, T., et al. (2022) · Nature · doi:10.1038/s41586-022-04424-7 · Cited by 574
Self-citationThe probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Phase separation and neurodegenerative diseases: a disturbance in the force
Zbinden, A., Pérez-Berlanga, M., De Rossi, P., & Polymenidou, M. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.09.014 · Cited by 500
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2023) · doi:10.1101/2023.05.08.539485 · Cited by 425
Biological subtypes of Alzheimer disease: A systematic review and meta-analysis
Ferreira, D., Nordberg, A., & Westman, E. (2020) · Neurology · doi:10.1212/wnl.0000000000009058 · Cited by 422
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.13855 · Cited by 416
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01774-5 · Cited by 397
Jo, M., Lee, S., Jeon, Y.-M., Kim, S., Kwon, Y., & Kim, H.-J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00513-7 · Cited by 397
TDP-43 proteinopathies: a new wave of neurodegenerative diseases
de Boer, E. M. J., Orie, V. K., Williams, T., Baker, M. R., De Oliveira, H. M., Polvikoski, T., Silsby, M., Menon, P., van den Bos, M., Halliday, G. M., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322983 · Cited by 381
Self-citationNeuropathology of Alzheimer's Disease
Trejo-Lopez, J. A., Yachnis, A. T., & Prokop, S. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 378
TDP-43 Pathology in Alzheimer’s Disease
Meneses, A., Koga, S., O’Leary, J., Dickson, D. W., Bu, G., & Zhao, N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00503-x · Cited by 363
Self-citationHSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells
Yu, H., Lu, S., Gasior, K., Singh, D., Vazquez-Sanchez, S., Tapia, O., Toprani, D., Beccari, M. S., Yates, J. R., Da Cruz, S., et al. (2021) · Science · doi:10.1126/science.abb4309 · Cited by 353
FUS and TDP-43 Phases in Health and Disease
Portz, B., Lee, B. L., & Shorter, J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.005 · Cited by 327
Jack, C. R., Wiste, H. J., Therneau, T. M., Weigand, S. D., Knopman, D. S., Mielke, M. M., Lowe, V. J., Vemuri, P., Machulda, M. M., Schwarz, C. G., et al. (2019) · JAMA · doi:10.1001/jama.2019.7437 · Cited by 324
Self-citationInterpretation of risk loci from genome-wide association studies of Alzheimer's disease
Andrews, S. J., Fulton-Howard, B., & Goate, A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30435-1 · Cited by 314
“2 X18 rs59685680 15:51001534:T:G SPPL2A (19) 0.247 0.93 (0.91–0.96) 9.2E-09 15q21.”
InfluentialAttems, J., Toledo, J. B., Walker, L., Gelpi, E., Gentleman, S., Halliday, G., Hortobagyi, T., Jellinger, K., Kovacs, G. G., Lee, E. B., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02255-2 · Cited by 280
Self-citationComorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278
“sent, limbic-predominant (LATE-NC stages I and II) or diffuse (LATE-NC stage III) according to published criteria.(8) AGD was assessed as previously described,(27) and staged as absent, limbic-”
MethodSelf-citationThe path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Cryo-EM structures of four polymorphic TDP-43 amyloid cores
Cao, Q., Boyer, D. R., Sawaya, M. R., Ge, P., & Eisenberg, D. S. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0248-4 · Cited by 251
Molecular pathology of neurodegenerative diseases: principles and practice
Kovacs, G. G. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205952 · Cited by 242
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
“been hypothesized [77], called limbic-predominant”
TDP-43 condensation properties specify its RNA-binding and regulatory repertoire
Hallegger, M., Chakrabarti, A. M., Lee, F. C. Y., Lee, B. L., Amalietti, A. G., Odeh, H. M., Copley, K. E., Rubien, J. D., Portz, B., Kuret, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.018 · Cited by 240
“Post-mortem tissue from 97% of individuals with ALS presents TDP-43 aggregates, and TDP-43 proteinopathy is also common in frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE) and Alzheimer’s disease (Gao et al., 2019; Nelson et al., 2019).”
BackgroundMechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Baughn, M. W., Melamed, Z., López-Erauskin, J., Beccari, M. S., Ling, K., Zuberi, A., Presa, M., Gonzalo-Gil, E., Maimon, R., Vazquez-Sanchez, S., et al. (2023) · Science · doi:10.1126/science.abq5622 · Cited by 239
Root, J., Merino, P., Nuckols, A., Johnson, M., & Kukar, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105360 · Cited by 238
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
Smirnov, D. S., Ashton, N. J., Blennow, K., Zetterberg, H., Simrén, J., Lantero-Rodriguez, J., Karikari, T. K., Hiniker, A., Rissman, R. A., Salmon, D. P., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02408-5 · Cited by 221
Self-citationTo what degree is late life cognitive decline driven by age-related neuropathologies?
Boyle, P. A., Wang, T., Yu, L., Wilson, R. S., Dawe, R., Arfanakis, K., Schneider, J. A., & Bennett, D. A. (2021) · Brain · doi:10.1093/brain/awab092 · Cited by 219
Self-citationBoeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217
Progranulin as a therapeutic target in neurodegenerative diseases
Rhinn, H., Tatton, N., McCaughey, S., Kurnellas, M., & Rosenthal, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.015 · Cited by 208
Prevalence and clinical phenotype of quadruple misfolded proteins in older adults
Karanth, S., Nelson, P. T., Katsumata, Y., Kryscio, R. J., Schmitt, F. A., Fardo, D. W., Cykowski, M. D., Jicha, G. A., Van Eldik, L. J., & Abner, E. L. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1741 · Cited by 206
Self-citationThe development and convergence of co-pathologies in Alzheimer’s disease
Robinson, J. L., Richardson, H., Xie, S. X., Suh, E., Van Deerlin, V. M., Alfaro, B., Loh, N., Porras-Paniagua, M., Nirschl, J. J., Wolk, D., et al. (2021) · Brain · doi:10.1093/brain/awaa438 · Cited by 203
“Second, copathologies may also lower the threshold for, and contribute to the clinical symptoms of Alzheimer’s disease as primary neurodegenerative processes that are subsequently overwhelmed by Alzheimer’s disease pathology (Jellinger, 2002; Kapasi et al., 2017; Nelson et al., 2019).”
BackgroundSelf-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 205
Self-citationJack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200
Self-citationBlevins, B. L., Vinters, H. V., Love, S., Wilcock, D. M., Grinberg, L. T., Schneider, J. A., Kalaria, R. N., Katsumata, Y., Gold, B. T., Wang, D. J. J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02235-6 · Cited by 200
Self-citationDesigning the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191
Novak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187
Dementia in Africa: current evidence, knowledge gaps, and future directions
Akinyemi, R. O., Yaria, J., Ojagbemi, A., Guerchet, M., Okubadejo, N., Njamnshi, A. K., Sarfo, F. S., Akpalu, A., Ogbole, G., Ayantayo, T., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12432 · Cited by 184
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 184
Phase separation-deficient TDP43 remains functional in splicing
Schmidt, H. B., Barreau, A., & Rohatgi, R. (2019) · Nature Communications · doi:10.1038/s41467-019-12740-2 · Cited by 178
Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated
Robinson, J. L., Xie, S. X., Baer, D. R., Suh, E., Van Deerlin, V. M., Loh, N. J., Irwin, D. J., McMillan, C. T., Wolk, D. A., Chen-Plotkin, A., et al. (2023) · Brain · doi:10.1093/brain/awad059 · Cited by 176
Self-citationLATE-NC staging in routine neuropathologic diagnosis: an update
Nelson, P. T., Lee, E. B., Cykowski, M. D., Alafuzoff, I., Arfanakis, K., Attems, J., Brayne, C., Corrada, M. M., Dugger, B. N., Flanagan, M. E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-022-02524-2 · Cited by 176
Self-citationNelson, P. T., Brayne, C., Flanagan, M. E., Abner, E. L., Agrawal, S., Attems, J., Castellani, R. J., Corrada, M. M., Cykowski, M. D., Di, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02444-1 · Cited by 174
Self-citationCerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
Johnson, E. C. B., Bian, S., Haque, R. U., Carter, E. K., Watson, C. M., Gordon, B. A., Ping, L., Duong, D. M., Epstein, M. P., McDade, E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02476-4 · Cited by 170
“Autosomal dominantly inherited forms of AD and sporadic LOAD have been shown to have similar pathophysiology 14,60 , but it is possible that there may be differences between ADAD and LOAD that could influence the sequence and degree of biomarker changes observed.”
BackgroundInfluentialSelf-citationMinoshima, S., Cross, D., Thientunyakit, T., Foster, N. L., & Drzezga, A. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263194 · Cited by 170
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02449-2 · Cited by 169
Disentangling Heterogeneity in Alzheimer’s Disease and Related Dementias Using Data-Driven Methods
Habes, M., Grothe, M. J., Tunc, B., McMillan, C., Wolk, D. A., & Davatzikos, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.016 · Cited by 167
Epidemiology of neurological diseases in older adults
Dumurgier, J., & Tzourio, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.356 · Cited by 167
Intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates
Yan, X., Kuster, D., Mohanty, P., Nijssen, J., Pombo-García, K., Garcia Morato, J., Rizuan, A., Franzmann, T. M., Sergeeva, A., Ly, A. M., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.039 · Cited by 167
Self-citationAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD
Irwin, K. E., Jasin, P., Braunstein, K. E., Sinha, I. R., Garret, M. A., Bowden, K. D., Chang, K., Troncoso, J. C., Moghekar, A., Oh, E. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02788-5 · Cited by 163
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
Smailovic, U., & Jelic, V. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00169-0 · Cited by 136
Ossenkoppele, R., Lyoo, C. H., Jester-Broms, J., Sudre, C. H., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.5154 · Cited by 161
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
Frisoni, G. B., Festari, C., Massa, F., Cotta Ramusino, M., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Borroni, B., Cappa, S. F., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00447-7 · Cited by 161
Lu, S., Hu, J., Arogundade, O. A., Goginashvili, A., Vazquez-Sanchez, S., Diedrich, J. K., Gu, J., Blum, J., Oung, S., Ye, Q., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00988-8 · Cited by 161
Invited Review: The role of prion‐like mechanisms in neurodegenerative diseases
Jaunmuktane, Z., & Brandner, S. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12592 · Cited by 150
Clinical effects of Lewy body pathology in cognitively impaired individuals
Quadalti, C., Palmqvist, S., Hall, S., Rossi, M., Mammana, A., Janelidze, S., Dellavalle, S., Mattsson-Carlgren, N., Baiardi, S., Stomrud, E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02449-7 · Cited by 160
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
“The reasons are manifold — a part of decline is driven by various common comorbidities such as vascular, TDP43 [214], or alpha-synuclein pathology [215]; the cognitive performance of patients varies on a day-to-day basis [216]; the clinical assessment tools are not perfect [217]; the margin of…”
BackgroundOverview of Transgenic Mouse Models for Alzheimer's Disease
Myers, A., & McGonigle, P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.81 · Cited by 142
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 144
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00779-6 · Cited by 145
Roemer, S. F., Grinberg, L. T., Crary, J. F., Seeley, W. W., McKee, A. C., Kovács, G. G., Beach, T. G., Duyckaerts, C. J., Ferrer, I., Gelpí, E., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02479-4 · Cited by 139
Self-citationSpecific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties
Grese, Z. R., Bastos, A. C. S., Mamede, L. D., French, R. L., Miller, T. M., & Ayala, Y. M. (2021) · EMBO Reports · doi:10.15252/embr.202153632 · Cited by 138
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 131
Sperling, R. A., Donohue, M., Rissman, R. A., Johnson, K. A., Rentz, D. M., Grill, J. D., Heidebrink, J. L., Jenkins, C., Jimenez‐Maggiora, G. A., Langford, O., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.122 · Cited by 139
Self-citationThe basis of clinicopathological heterogeneity in TDP-43 proteinopathy
Kawakami, I., Arai, T., & Hasegawa, M. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02077-x · Cited by 132
Alzheimer's disease outlook: controversies and future directions
Frisoni, G. B., Aho, E., Brayne, C., Ciccarelli, O., Dubois, B., Fox, N. C., Frederiksen, K. S., Gabay, C., Garibotto, V., Hofmarcher, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01389-3 · Cited by 135
Self-citationStaging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease
Ossenkoppele, R., Lyoo, C. H., Sudre, C. H., van Westen, D., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.08.201 · Cited by 121
Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer’s disease
Tetreault, A. M., Phan, T. X., Orlando, D., Lyu, I., Kang, H., Landman, B. A., Darby, R. R., & Initiative, O. B. O. A. D. N. (2020) · Brain · doi:10.1093/brain/awaa058 · Cited by 130
Yang, Z., Nasrallah, I. M., Shou, H., Wen, J., Doshi, J., Habes, M., Erus, G., Abdulkadir, A., Resnick, S. M., Albert, M. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26703-z · Cited by 100
Self-citationXia, Y., Prokop, S., Gorion, K.-M. M., Kim, J. D., Sorrentino, Z. A., Bell, B. M., Manaois, A. N., Chakrabarty, P., Davies, P., & Giasson, B. I. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00967-w · Cited by 114
Neumann, M., Lee, E. B., & Mackenzie, I. R. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-51140-1_13 · Cited by 103
Neuropathology and emerging biomarkers in corticobasal syndrome
Koga, S., Josephs, K. A., Aiba, I., Yoshida, M., & Dickson, D. W. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328586 · Cited by 127
Self-citationHead-to-Tail Polymerization in the Assembly of Biomolecular Condensates
Bienz, M. (2020) · Cell · doi:10.1016/j.cell.2020.07.037 · Cited by 117
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Toledo, J. B., Ruiz, C. A., Weil, R. S., Ferreira, D., Rodriguez‐Porcel, F. E., Pilotto, A., Wyman‐Chick, K. A., Grothe, M. J., Kane, J. P. M., Taylor, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12814 · Cited by 121
McAleese, K. E., Colloby, S. J., Thomas, A. J., Al‐Sarraj, S., Ansorge, O., Neal, J., Roncaroli, F., Love, S., Francis, P. T., & Attems, J. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12291 · Cited by 108
Self-citationPredicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
“Individuals who have highly aggressive Alzheimer’s disease either do not survive to old age or if they do survive are too impaired to participate in longitudinal observational studies because of the combination of an aggressive Alzheimer’s disease phenotype plus non-Alzheimer’s brain pathologies common in old age (Nel…”
BackgroundSelf-citationKlein, H., Trumpff, C., Yang, H., Lee, A., Picard, M. A., Bennett, D. A., & Jager, P. L. D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00495-8 · Cited by 117
Besser, L. M., Teylan, M. A., & Nelson, P. T. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz126 · Cited by 107
Self-citationAn update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Simrén, J., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.019 · Cited by 107
Tomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 112
The Role of TDP-43 in Neurodegenerative Disease
Liao, Y.-Z., Ma, J., & Dou, J.-Z. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02847-x · Cited by 111
Feng, T., Lacrampe, A., & Hu, F. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02246-3 · Cited by 110
“Reduced brain size (rs1990620) Decreased neuron proportion (rs1990621) Worse cognitive decline (rs1990622) [14, 20, 21, 29, 42, 43, 57, 76, 78, 79] FTLD-C9ORF72 rs1990622 rs3173615 T C C G Major allele associated with later onset and age at death Fewer minor allele homozygotes found in FTLD-C9ORF72 cases [17, 22, 77]…”
BackgroundInfluentialContribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease
de Flores, R., Wisse, L. E. M., Das, S. R., Xie, L., McMillan, C. T., Trojanowski, J. Q., Robinson, J. L., Grossman, M., Lee, E., Irwin, D. J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12079 · Cited by 102
Self-citationCurrent Concepts of Mixed Pathologies in Neurodegenerative Diseases
Forrest, S. L., & Kovács, G. G. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.34 · Cited by 110
Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C
Arseni, D., Nonaka, T., Jacobsen, M. H., Murzin, A. G., Cracco, L., Peak‐Chew, S., Garringer, H. J., Kawakami, I., Suzuki, H., Onaya, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08024-5 · Cited by 111
Self-citationLatimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., Henriksen, J., Darvas, M., Domoto-Reilly, K., Jayadev, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0743-1 · Cited by 97
Self-citationThe coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease
Boon, B. D. C., Bulk, M., Jonker, A. J., Morrema, T. H. J., van den Berg, E., Popovic, M., Walter, J., Kumar, S., van der Lee, S. J., Holstege, H., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02198-8 · Cited by 93
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
Wolk, D. A., Nelson, P. T., Apostolova, L. G., Arfanakis, K., Boyle, P. A., Carlsson, C. M., Corriveau‐Lecavalier, N., Dacks, P. A., Dickerson, B. C., Domoto‐Reilly, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14202 · Cited by 110
Self-citationFazal, R., Boeynaems, S., Swijsen, A., De Decker, M., Fumagalli, L., Moisse, M., Vanneste, J., Guo, W., Boon, R., Vercruysse, T., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106177 · Cited by 108
“Recently, TDP-43 pathology has also been identified in age-related encephalopathies and is found in about 25% of individuals above the age of 80 years (Nelson et al , 2019).”
Nichols, E., Merrick, R., Hay, S. I., Himali, D., Himali, J. J., Hunter, S., Keage, H. A. D., Latimer, C. S., Scott, M. R., Steinmetz, J. D., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00019-3 · Cited by 108
Self-citationSánchez‐Juan, P., Valeriano-Lorenzo, E., Ruiz-González, A., Pastor, A. B., Lara, H. R., López-González, F., Zea‐Sevilla, M. A., Valentí, M., Payo, B. F., Ruiz, P., et al. (2024) · Brain · doi:10.1093/brain/awae035 · Cited by 108
Beyond the average patient: how neuroimaging models can address heterogeneity in dementia
Verdi, S., Marquand, A. F., Schott, J. M., & Cole, J. H. (2021) · Brain · doi:10.1093/brain/awab165 · Cited by 106
“Dementia is the end point of multiple diseases, including Alzheimer’s disease, vascular dementia, Parkinson’s disease dementia, dementia with Lewy bodies, frontotemporal dementia and limbic-predominant age-related TDP-43 encephalopathy (LATE).(3,4) Neuropathological factors vary between these diseases, though commonly…”
Background
Metadata
- Authors
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., Coyle-Gilchrist, I. T. S., Chui, H. C., Fardo, D. W., Flanagan, M. E., Halliday, G., Hokkanen, S. R. K., Hunter, S., Jicha, G. A., Katsumata, Y., Kawas, C. H., Keene, C. D., Kovacs, G. G., Kukull, W. A., Levey, A. I., Makkinejad, N., Montine, T. J., Murayama, S., Murray, M. E., Nag, S., Rissman, R. A., Seeley, W. W., Sperling, R. A., White III, C. L., Yu, L., & Schneider, J. A.
- Affiliations
- University of Kentucky (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- Rush University Medical Center (US)
- Uppsala University (SE)
- Newcastle University (GB)
- University of Cambridge (GB)
- University of Southern California (US)
- University of Minnesota (US)
- The University of Sydney (AU)
- University of California, Irvine (US)
- University of Washington (US)
- Institute of Neurology Medical University of Vienna, Vienna, Austria
- Emory University (US)
- Illinois Institute of Technology (US)
- Stanford University (US)
- Tokyo Metropolitan Institute of Gerontology (JP)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Harvard University (US)
- University of Texas Southwestern Medical Center, Dallas, TX, USA
- Corresponding author
- Nelson, Peter T
- ORCID
- Nelson, Peter T
- Dickson, Dennis W
- Trojanowski, John Q
- Jack, Clifford R
- Boyle, Patricia A
- Arfanakis, Konstantinos
- Rademakers, Rosa
- Alafuzoff, Irina
- Attems, Johannes
- Brayne, Carol
- Coyle-Gilchrist, Ian T S
- Chui, Helena C
- Fardo, David W
- Flanagan, Margaret E
- Halliday, Glenda
- Hokkanen, Suvi R K
- Hunter, Sally
- Jicha, Gregory A
- Katsumata, Yuriko
- Kawas, Claudia H
- Keene, C Dirk
- Kukull, Walter A
- Levey, Allan I
- Makkinejad, Nazanin
- Montine, Thomas J
- Murayama, Shigeo
- Murray, Melissa E
- Nag, Sukriti
- Rissman, Robert A
- Seeley, William W
- Sperling, Reisa A
- Yu, Lei
- Schneider, Julie A
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-30
- Volume
- 142
- Issue
- 6
- Pages
- 1503-1527
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6536849
- OpenAlex
- W2943828894
- Cited by
- 1,547
- References
- 276
- Citations by year
- 2026: 206 · 2025: 240 · 2024: 211 · 2023: 214 · 2022: 213 · 2021: 193 · 2020: 198 · 2019: 66
- FWCI
- 113.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- NIA
- NACC
- NIH (U01 AG016976)
- National Health and Medical Research Council
- NHMRC (1132524, 1095127, 1037746)
- Senior Principal Research Fellowship (1079679)
- National Institutes of Health (P01 AG003949, R01 AG037491, P50 AG016574, R01 AG054449, P30 AG028303, P30 AG012300, P30 AG049638, P30 AG010124, P30 AG010161, P50 AG047366, P50 AG025688, P50 AG005131, R37 AG011378, R01 AG041851, R01 AG042210, R01 AG017917, R01 AG034374, UF1 AG053983, UF1 AG057707)
- NIHR (534906, NF-SI-0616–10090)
- National Institute for Health Research
- NHS
- Department of Health and Social Care
- Addenbrooke’s Charitable Trust
- Paul G. Allen Family Foundation and Alzheimer’s Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- limbic-predominant age-related TDP-43 encephalopathy, TDP-43 proteinopathy, hippocampal sclerosis, diagnostic criteria, neuropathological staging, amygdala, medial temporal lobe atrophy, genetic risk variants, gene regulatory networks, TMEM106B, ABCC9, apolipoprotein E, Alzheimer's disease, frontotemporal lobar degeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Diseases, Female, Humans, Male, Middle Aged, Retrospective Studies, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.